Followers | 162 |
Posts | 8119 |
Boards Moderated | 0 |
Alias Born | 10/31/2007 |
Tuesday, May 26, 2009 3:35:21 PM
United Therapeutics Corp. $ 73.85
UTHR 7.31
Short Interest (Shares Short) 3,669,300
Days To Cover (Short Interest Ratio) 4.9
Short Percent of Float 14.36 %
Short Interest - Prior 3,565,800
Short % Increase / Decrease 2.90 %
Short Squeeze Ranking™ -19
% From 52-Wk High ($ 117.82 ) -59.54 %
% From 52-Wk Low ($ 47.63 ) 35.50 %
% From 200-Day MA ($ 64.73 ) 12.35 %
% From 50-Day MA ($ 62.65 ) 15.17 %
Price % Change (52-Week) -27.00 %
Shares Float 25,560,000
Total Shares Outstanding 26,451,577
% Owned by Insiders %
% Owned by Institutions %
Market Cap. $ 1,953,448,961
Trading Volume - Today 2,144,362
Trading Volume - Average 750,900
Trading Volume - Today vs. Average 285.57 %
Earnings Per Share -1.84
PE Ratio
Record Date 2009-MayA
Sector Healthcare
Industry Drug Manufacturers - Other
Exchange NAS
Recent UTHR News
- United Therapeutics Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/01/2024 10:30:00 AM
- CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant • Business Wire • 04/26/2024 06:02:00 PM
- United Therapeutics Announces World’s First Successful Xenothymokidney Transplant • Business Wire • 04/24/2024 01:00:00 PM
- United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024 • Business Wire • 04/24/2024 11:00:00 AM
- United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference • Business Wire • 04/16/2024 11:00:00 AM
- United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation • Business Wire • 03/26/2024 11:00:00 AM
- United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program • Business Wire • 03/25/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:30:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:30:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:52:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:30:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:30:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:18:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:33:06 PM
- United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024 • Business Wire • 03/05/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:33:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:50:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:03:12 AM
- United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/27/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:31:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:30:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:30:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2024 09:08:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM